ArticleFrontiers in medicine2025
Evaluating diagnostic yield and accuracy as key performance metrics in pulmonary lung lesions.
Article in Frontiers in medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Predictors of Diagnostic Yield in Shape-Sensing Robotic-Assisted Bronchoscopy (ssRAB): A Retrospective Single-Center Study.Diagnostics (Basel, Switzerland) · 2026Article
- Learning Curve of Shape-Sensing Robotic-Assisted Bronchoscopy (ssRAB) for Peripheral Pulmonary Lesions in a Thoracic Surgery Center Using the ION System.Journal of clinical medicine · 2026Article
- Radiomics to understand pre-treatment tumor biology for resectable non-small cell lung cancer.Frontiers in oncology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: A conservative definition of diagnostic yields for assessing the performance of guided bronchoscopy has been proposed, but it has yet to be validated in practice. Methods: Patients who underwent radial endobronchial ultrasound (R-EBUS) between April 2020 and April 2023 were included in the study. Diagnostic results were classified as malignant or non-malignant based on the post-lung-biopsy pathology. Non-malignant results were further categorized into specific benign (SB), nonspecific benign (NSB), atypical cells, and non-diagnostic (ND). All non-malignant lesions were confirmed using alternative biopsy methods or chest computed tomography (CT) during a follow-up of over 1 year. Diagnostic yield and accuracy were calculated using pre-defined methods (Box below). Predictors of sampling success were identified in a logistic regression analysis. Results: Among the 736 patients evaluated in this study, R-EBUS-guided TBLB revealed malignancy in 431 (58.6%) patients. The remaining 305 (41.4%) patients with non-malignant lesions were classified as SB (8.3%), NSB (21.3%), atypia (4.6%), and ND (7.2%). Diagnostic yield vs. accuracy values based on conservative, intermediate, and liberal definitions were 67% vs. 67, 88% vs. 77, and 100% vs. 79%, respectively. Thus, for the conservative definition, diagnostic accuracy and diagnostic yield were identical. Significant predictive factors for successful lung biopsy according to the conservative diagnostic yield included lesion size (> 20 mm), CT-bronchus subclassification (Ia, Ib), and radial probe position within the lesion. Conclusion: Our study validated the use of the conservative definition of diagnostic yield as a reliable diagnostic endpoint for evaluating the performance of guided bronchoscopy. This definition could serve as a time-saving standard in prospective studies comparing the diagnostic effectiveness of various navigation devices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.